Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 2/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3605345 | 0.77 | DRD4 (0.46) | MEN1KMT2ATDP1PDE10ADRD4 | |
| SCHEMBL2215763 | 0.77 | NPSR1 (0.46) | MEN1KMT2ATDP1L3MBTL1MAPT | |
| SCHEMBL5764 | 0.70 | MEN1 (1.00) | MEN1KMT2ATDP1DRD4MAOA | |
| Toluene SCHEMBL16880241 | 0.69 | MEN1 (0.77) | MEN1KMT2ATDP1DRD4MAOA | |
| Water SCHEMBL4230715 | 0.68 | MEN1 (0.94) | MEN1KMT2ATDP1DRD4MAOA | |
| SCHEMBL4922899 | 0.68 | MEN1 (0.94) | MEN1KMT2ATDP1DRD4MAOA | |
| SCHEMBL5040570 | 0.68 | MEN1 (0.94) | MEN1KMT2ATDP1DRD4MAOA | |
| Ammonia Solution, Strong SCHEMBL6678345 | 0.68 | MEN1 (0.94) | MEN1KMT2ATDP1DRD4MAOA | |
| SCHEMBL4913828 | 0.68 | MEN1 (0.94) | MEN1KMT2ATDP1DRD4MAOA | |
| Hydrochloric Acid SCHEMBL5845845 | 0.68 | MEN1 (0.94) | MEN1KMT2ATDP1DRD4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102216292-B | Tetrasubstituted pyridazines HEDGEHOG pathway antagonists | LILLY CO ELI | 2014-08-13 | — | — | CN | disclosed |
| EP-2358703-B1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | LILLY CO ELI (US) | 2013-12-25 | — | — | EP | disclosed |
| US-8445493-B2 | Tetrasubstituted pyridazines hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445493-B2 | Tetrasubstituted pyridazines hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110178093-A1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178093-A1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2010056620-A1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178093-A1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | SMO, SHH, GLI1 | MEN1 2367/4885KMT2A 1484/4885TDP1 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.